帝國集團環球控股(00776.HK)與一家日本遊戲公司訂立遊戲獨家代理許可協議
格隆匯8月18日丨帝國集團環球控股(00776.HK)發佈公告,於2020年8月18日,獲許可方七元素遊戲有限公司(公司全資附屬公司)與許可方Asobimo, Inc.訂立許可協議,據此,獲許可方獲授權擔任獨家代理,在指定地區營銷、發行、營運及分銷手機遊戲的獨家代理,自簽訂許可協議日期起計初步為期三年,並可於期滿時續期。
獲許可方須於商業化推出日期後12個月內透過在指定地區實施其線上或線下營銷計劃(包括廣告、共同合作、新聞發佈會或其他非免費增值營銷活動),投資最少金額150萬美元以推廣手機遊戲。
許可方為一家於日本東京註冊成立的公司,主要從事網絡遊戲的開發及營運。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.